Introduction
With more than 80 different types of autoimmune disorders affecting all organ systems in the human body, finding a drug which would treat patients at the root cause of these diseases has been a quest of our mutual labs for the past two decades. These diseases may range from mild skin disorders such as psoriasis, widely distributed joint damage such as in rheumatoid arthritis, destruction of specific cells such as β cells in type-1 diabetes to more complex disorders affecting central nervous system such as multiple sclerosis. Current treatments involve the use of broad immunosuppressants, which may open the door to opportunistic infections. Through work pioneered with the Chandy lab, we have shown that the channel phenotypes of these autoantigen specific T-cells have preferentially upregulated the Kv1.3 channel to balance Ca +2 influx upon activation. A sea anemone derived peptide named ShK is one of the most potent Kv1.3 blockers described (IC50 = 10 pM), however it lacks specificity and blocks Kv1.1 and Kv1.5 also at pM levels [1, 2] . Through many years of engineering, we have progressed one of our peptides, Dalazatide (formerly ShK-186) to the clinic for its selective block of Kv1.3 channels as a means of treating autoimmune diseases. In our current work, we have built upon our findings to continue to improve the selectivity of ShK-derived analogs and have recently reported selectivity profiles of more than 1000x for Kv1.3 versus Kv1.1. We have improved the drugability of ShK [3, 4] .
Results and Discussion
Several analogs were designed to investigate the effect of Q16K or K18A substitution on the selectivity and potency of ShK analogs previous reported, such as ShK-192 and ShK analog with N-terminal extension EWSS ( Figure 1 ) [3] . The analogs were designed to include a substitution that a group at Amgen had published in a patent filed in 2007. This substitution replaced Gln16 with Lys. The results presented in that patent suggested that this substitution conferred on ShK a high Kv1.3 versus Kv1.1 specificity. Thus, we incorporated this substitution into ShK-192, which incorporated a nonhydrolyzable para-phosphono-Phe (Ppa) as the N-terminal residue, extended from the primary ShK sequence with an Aeea (aminoethyloxyethyloxyacetyl, mini-Peg™) linker, as well as amidation at the C-terminus (ShK-224). We also incorporated a Met21 to Nle substitution into this sequence to generate an analog that would be less susceptible to oxidation (ShK-223). We also designed two more analogs by replacing the N-terminal extension of ShK-192 (Ppa-Aeea) with EWSS extension [3] and replacing Qln16 with K (ShK-237), and Lys18 with Ala (ShK-238). The EWSS extension consists of only common proteins amino acids, and it was designed to resemble the structure of the ShK-192 N-terminal extension [3] .
All the analogs were synthesized on a Rink-mBHA resin using an Fmoc-tBu strategy, except for ShK-239 that was synthesized on a Wang resin. The solid-phase assembly proceeded smoothly with all couplings mediated by 6-Cl-HOBT and diisopropylcarbodiimide. In order to form the disulfide bonds utilizing a simple redox buffer, all Cys residues were protected with the trityl group. Following synthesis of the primary chain, each peptide was cleaved from the resin and simultaneously deprotected using an acidolytic reagent cocktail containing carbocation scavengers. The peptides were folded to the active form using a slightly basic aqueous buffer containing an equimolar ratio of reduced and oxidized glutathione. The peptide folding was done for a period of 16 h and was determined to be complete with the formation of the major front eluting peak consistent with other ShK peptides. Each peptide was purified by RP-HPLC and the purified peptides were characterized by analytical HPLC and ESI-MS.
Fig. 1. N-terminal extensions of ShK analogues. Schematic illustrating the structural similarity and physicochemical properties of Ppa moiety of ShK-192 and various amino acid extensions.
We used patch-clamp electrophysiology to assess the effects of ShK-223, ShK-224, ShK-237, ShK-238 and ShK-239 on Kv1.1 and Kv1.3 channels and compare them to the parent peptide, ShK and ShK-192. Mouse fibroblasts stably expressing homotetramers of Kv1.1 or Kv1.3 were patch-clamped in the whole-cell configuration and steady-state block was measured after addition of different concentrations of the peptides. As published previously, ShK inhibited Kv1.3 currents with an IC50 of 10 pM and Kv1.1 currents with an IC50 of 25 pM (Table 1) . ShK-224 exhibited a 16-fold loss of efficacy on Kv1.3 relative to ShK, ShK-237 a 26-fold loss, ShK-238 a 9-fold loss and ShK-239 a 3-fold loss, whereas the potency of ShK-223 on Kv1.3 was similar to that of ShK (Table 1) . Unlike ShK, ShK-238 exhibited a 28-fold selectivity for Kv1.3 over Kv1.1, and ShK-239 a 158-fold selectivity, while ShK-223, ShK-224 and ShK-237 had any effect on Kv1.1 currents at concentrations up to 100 nM, representing a selectivity for Kv1.3 of >10,000-fold. . The Q16K substitution coupled with either the Ppa-Aeea or EWSS N-terminal extensions confers the greatest level of selectivity enhancement as shown in the ShK-223, ShK-224 and ShK-237. The K18A coupled with the EWSS N-terminal extension lost more than 10x of its gain of the singly substituted ShK-K18A [5] .
